CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic analog of Growth Hormone-Releasing Hormone (GHRH) from Pyrex Labs. Designed for researchers requiring sustained growth hormone release in their experimental models, this 5mg vial features the proprietary DAC modification that covalently binds to serum albumin, protecting the peptide from rapid enzymatic breakdown.

Unlike standard GHRH analogs with half-lives measured in minutes, CJC-1295 with DAC extends the active window to approximately 6-8 days. Single administrations have been shown in research settings to elevate growth hormone and IGF-1 levels for up to 11-14 days, making this compound uniquely suited for studies examining prolonged GH exposure.

Each vial contains a potent 5mg formulation of this GHRH analogue, lyophilized into a stable white powder using advanced freeze-drying techniques. Every batch is tested in the USA to confirm minimum 99% purity, ensuring your long-term research protocols remain free from contaminant interference.

Key Research Applications

• Sustained GH Release Studies: Investigates the effects of prolonged, stable growth hormone elevation over days rather than hours

• Metabolic Pathway Research: Explores hormone-mediated energy output, fat metabolism, and lean tissue preservation under extended GH exposure

• Chronic Recovery Models: Examines systemic recovery mechanisms, soft tissue repair, and cellular healing over extended observation periods

• IGF-1 Modulation Research: Studies the downstream effects of sustained GHRH stimulation on insulin-like growth factor pathways

Distinguishing Features

Specifications

Reconstitution Guidance

Reconstitute CJC-1295 with DAC using bacteriostatic water (0.9% benzyl alcohol) for extended laboratory storage, or sterile water for single-use aliquots. Direct diluent gently down the inner wall of the vial rather than onto the lyophilized cake. Swirl slowly until fully dissolved — do not shake.

Choose a reconstitution volume that matches your experimental protocol. Many investigators use 1-2 mL per vial and immediately aliquot into single-use tubes to avoid repeated freeze-thaw cycles, which is the primary cause of peptide degradation in long-acting formulations.

Storage & Stability

Before Reconstitution: Store the unopened, lyophilized vial at −20°C in a desiccated, light-protected environment. Pyrex Labs lyophilized cakes remain stable under these conditions for the shelf-life indicated on the certificate of analysis.

After Reconstitution: Store the solution at 2–8°C and use within 14 days. Long-term storage of working solutions at −20°C is acceptable only when single-use aliquots are prepared at reconstitution. Do not subject the reconstituted peptide to repeated freeze-thaw cycles.

Quality Assurance

Every lot of CJC-1295 with DAC undergoes comprehensive release testing against internal specifications, including:

• Reverse-phase HPLC for purity confirmation (≥99%)

• ESI mass spectrometry for identity verification

• Karl Fischer testing for residual moisture in the lyophilized cake

• Visual inspection of vial integrity

Each vial is laser-coded with a lot number that links directly to the chromatograms and MS traces produced during release testing. Lots falling outside specification are held pending investigation and are never shipped. A lot-specific Certificate of Analysis (COA) is available upon request.

Important Research Notes

Historical Clinical Context: CJC-1295 with DAC advanced into human clinical trials, including a Phase II study for HIV-related lipodystrophy. While the drug was ultimately withdrawn from development, these trials established the compound’s extended half-life profile and provided the foundational pharmacokinetic data that researchers rely upon today.

Reported Observations in Literature: Published studies have noted the following observations associated with CJC-1295 with DAC administration in research settings:

• Injection site reactions (pain, swelling, erythema) — most frequently observed

• Headache and flushing (vasodilation)

• Nausea and gastrointestinal discomfort

• Sustained elevation of GH and IGF-1 lasting 11-14 days post-administration

Researchers should consult primary peer-reviewed literature (PubMed, Google Scholar) before designing studies and validate dose ranges, vehicle compatibility, and analytical methodology against original published methods.

Related Products from Pyrex Labs

Researchers who order CJC-1295 with DAC frequently also purchase:

• CJC-1295 No DAC (5mg) – for pulsatile GH release comparisons

• Ipamorelin (5mg) – for selective GH secretagogue studies

• Mod GRF 1-29 & Ipamorelin Blend (10mg)

• Sermorelin & Ipamorelin Blend (10mg)

• Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)

Shipping & Ordering

Orders for CJC-1295 with DAC placed before daily cut-off ship same-day from our US warehouse. Each vial is packaged in cushioned, light-blocking materials inside plain, unbranded outer boxes for discreet delivery. US orders over $200 ship free. International shipping quotes available at checkout.

Frequently Asked Questions

What does DAC stand for? DAC stands for Drug Affinity Complex — a proprietary modification that allows the peptide to bind covalently to serum albumin, extending its half-life from minutes to days.

How is this different from CJC-1295 No DAC? CJC-1295 without DAC has a half-life of approximately 30 minutes and produces a short, sharp pulse of GH release that mimics natural GHRH. The version with DAC provides sustained, stable GH elevation over 6-8 days. Choose based on whether your research requires pulsatile or continuous GH exposure.

Is CJC-1295 with DAC approved for human use? No. This product is for research purposes only and is not FDA-approved for human consumption, medical treatment, or veterinary applications.

Do you provide a Certificate of Analysis? Yes. A lot-specific COA is available upon request for every vial shipped.